DE19904365A1 - Xantinol nicotinate medicament useful for treating circulatory disorders, joint affections and geriatric complaints includes procaine to reduce pain on injection - Google Patents

Xantinol nicotinate medicament useful for treating circulatory disorders, joint affections and geriatric complaints includes procaine to reduce pain on injection

Info

Publication number
DE19904365A1
DE19904365A1 DE1999104365 DE19904365A DE19904365A1 DE 19904365 A1 DE19904365 A1 DE 19904365A1 DE 1999104365 DE1999104365 DE 1999104365 DE 19904365 A DE19904365 A DE 19904365A DE 19904365 A1 DE19904365 A1 DE 19904365A1
Authority
DE
Germany
Prior art keywords
xantinol nicotinate
affections
joint
procaine
injection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE1999104365
Other languages
German (de)
Inventor
Guenter Hesse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to DE1999104365 priority Critical patent/DE19904365A1/en
Publication of DE19904365A1 publication Critical patent/DE19904365A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Medicament comprising xantinol nicotinate (I) and procaine (II) is new.

Description

Die üblichen Indikationen und Verabreichungen zur Anwendung von Xantinol-Nicotinat oral oder parenteral sind bekannt. Darüber hinaus hat sich ergeben, daß Xantinol-Nicotinat in geeigneter Lösung unter entsprechenden Kautelen via lokaler Injektion sowohl antidepressive als auch lokal­ hyperämissierende Eigenschaften hat.The usual indications and administrations for the use of xantinol nicotinate orally or are known parenterally. In addition, it has been found that xantinol nicotinate is more suitable Solution under appropriate caution via local injection both antidepressant and local has hyperemissive properties.

Um diese therapeutisch zu nutzen, ist die Kombination mit einem Anästhetikum erforderlich, da sub- oder intrakutan appliziertes Xantinol-Nicotinat an der Einstichstelle Schmerzen verursacht. Geeignet ist namentlich Procain in geeigneter Konzentration als Anästhetikum.To use this therapeutically, the combination with an anesthetic is necessary because Sub- or intracutaneously administered xantinol nicotinate causes pain at the injection site. Procaine in a suitable concentration is particularly suitable as an anesthetic.

Durch örtliche Xantinol-Nicotinat-Procain-Applikation in geeigneter Dosierung können sowohl Durchblutungsstörungen, Gelenk-Affektionen als auch andere pathologische Veränderungen er­ folgreich angegangen werden. Außerdem läßt sich Xantinol-Nicotinat-Procain zur Allgemeinthe­ rapie einsetzen, insbesondere in der Geriatrie, wo sich die positiven Effekte beider Mittel ergän­ zen.By local xantinol nicotinate procain application in a suitable dosage, both Circulatory disorders, joint affections as well as other pathological changes be tackled consequently. In addition, xantinol nicotinate procaine can be added to the general public use therapy, especially in geriatrics, where the positive effects of both agents complement each other Zen.

Schließlich eignet sich Xantinol-Nicotinat-Procain in Tablettenform zur oralen Behandlung.Finally, xantinol nicotinate procaine in tablet form is suitable for oral treatment.

Claims (2)

1. Die Erfindung betrifft das neue Medikament Xantinol-Nicotinat-Procain, dadurch gekenn­ zeichnet, daß die bekannte Kombination von Xantinol-Nicotinat durch das Anästhetikum Procain ergänzt wird, wodurch ein neuer Wirkstoff entsteht, mit dem z. B. Durchblutungsstö­ rungen, Gelenk-Affektionen sowie geriatrische Leiden erfolgreich behandelt werden können. Die neue Wirkstoffkombination bewirkt durch den Zusatz des Anästhetikums Procain eine Minimierung des bei der sub- oder intrakutanen Applikation von Xantinol-Nicotinat norma­ lerweise an der Einstichstelle auftretenden Schmerzes.1. The invention relates to the new drug xantinol nicotinate procain, characterized in that the known combination of xantinol nicotinate is supplemented by the anesthetic procaine, which creates a new active ingredient with which, for. B. circulatory disorders, joint affections and geriatric disorders can be successfully treated. By adding the anesthetic procaine, the new active ingredient combination minimizes the pain that usually occurs at the injection site when xantinol nicotinate is administered subcutaneously or intracutaneously. 2. Xantinol-Nicotinat-Procain nach Anspruch 1, dadurch gekennzeichnet, daß die Wirk­ stoffkombination auch in Tablettenform zur oralen Behandlung geeignet ist.2. xantinol nicotinate procaine according to claim 1, characterized in that the effect combination of substances is also suitable in tablet form for oral treatment.
DE1999104365 1999-02-03 1999-02-03 Xantinol nicotinate medicament useful for treating circulatory disorders, joint affections and geriatric complaints includes procaine to reduce pain on injection Withdrawn DE19904365A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE1999104365 DE19904365A1 (en) 1999-02-03 1999-02-03 Xantinol nicotinate medicament useful for treating circulatory disorders, joint affections and geriatric complaints includes procaine to reduce pain on injection

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE1999104365 DE19904365A1 (en) 1999-02-03 1999-02-03 Xantinol nicotinate medicament useful for treating circulatory disorders, joint affections and geriatric complaints includes procaine to reduce pain on injection

Publications (1)

Publication Number Publication Date
DE19904365A1 true DE19904365A1 (en) 2000-08-10

Family

ID=7896315

Family Applications (1)

Application Number Title Priority Date Filing Date
DE1999104365 Withdrawn DE19904365A1 (en) 1999-02-03 1999-02-03 Xantinol nicotinate medicament useful for treating circulatory disorders, joint affections and geriatric complaints includes procaine to reduce pain on injection

Country Status (1)

Country Link
DE (1) DE19904365A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105055345A (en) * 2015-09-02 2015-11-18 海南葫芦娃制药有限公司 Composition for injection of xantinol nicotinate, xantinol nicotinate lyophilized powder and preparation method thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105055345A (en) * 2015-09-02 2015-11-18 海南葫芦娃制药有限公司 Composition for injection of xantinol nicotinate, xantinol nicotinate lyophilized powder and preparation method thereof

Similar Documents

Publication Publication Date Title
EA200501496A1 (en) HIGH-SELECTIVE INHIBITORS OF REVERSE CAPTURE OF NOREPINEFRIN AND METHODS OF THEIR APPLICATION
ES2194025T3 (en) MULTIPLE BOTULINIC TOXINS TO TREAT DISORDERS AND NEUROMUSCULAR DISEASES.
KR960702318A (en) Treatment of muscle diseases and disorders
DE69533112D1 (en) USE OF FLAVOLIGNANES FOR THE PRODUCTION OF MEDICINES WITH ANTIPROLIFERATIVE ACTIVITY IN UTERUS, BREAST, EGGS
MY106075A (en) A method of treating anxiety-related disorders using sertraline.
DE3023588C2 (en) Use clonidine or its hydrochloride with phentermine to quit smoking
HUP0400548A2 (en) Use of combinations of iop-reducing active inoredient for preparation of pharmaceutical compositions available for treatment glaucoma
WO1999040883A3 (en) Compositions and methods for the treatment of cystic fibrosis
KR970061244A (en) Pharmaceutical composition for treating dementia
Nishiyama et al. Mexiletine for painful alcoholic neuropathy
DE19904365A1 (en) Xantinol nicotinate medicament useful for treating circulatory disorders, joint affections and geriatric complaints includes procaine to reduce pain on injection
Täschner A controlled comparison of clonidine and doxepin in the treatment of the opiate withdrawal syndrome
US4431670A (en) D-Phenylalanine treatment
KR970005283A (en) Use of sertraline to treat patients after myocardial infarction
DE60306503D1 (en) STATIN THERAPY FOR IMPROVING THE MAINTENANCE OF COGNITIVE FUNCTION
EP0649652B1 (en) Use of minimal-dose beta-blocker preparations
DE3626128C2 (en)
Lesse Combined tranylcypromine-trifluoperazine therapy in the treatment of patients with agitated depressions
DE60024408T2 (en) USE OF TRICYCLIC ANTIDEPRESSIVA FOR THE TREATMENT OF HEADACHE
English A comparative study of antidepressants in balanced therapy
US20020193435A1 (en) Nitroglycerin-menthol potentiation for treatment of angina
EP1632235A3 (en) Use of highly selective norepinephrine reuptake inhibitors for the treatment of mental disorders
JP2752250B2 (en) Basic therapeutic agent with analgesic and anti-inflammatory action
EP0402208A1 (en) Mixture of Vitamin A in physiological dosis and different active ingredients having therapeutic effect
CA2403674A1 (en) The use of t3 for treating congestive heart failure

Legal Events

Date Code Title Description
8139 Disposal/non-payment of the annual fee